ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "lymphocytes and rheumatoid arthritis (RA)"

  • Abstract Number: 88 • 2018 ACR/ARHP Annual Meeting

    Lymphocyte DNA Methylation As a Mediator of Genetic Risk in Rheumatoid Arthritis

    Alex Clark1,2, Nisha Nair3, Andrew Skelton1,2, Amy Anderson1,2, Nishanthi Thalayasingam1,2, Najib Naamane1,2, Julie Diboll1,2, Jonathan Massey4, Stephen Eyre3,4, Anne Barton3,4, John Isaacs1,2, Louise Reynard5 and Arthur Pratt1,2, 1Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, 2NIHR, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, 3Arthritis Research UK Centre for Genetics and Genomics and Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, 4NIHR Manchester Musculoskeletal Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester, United Kingdom, 5Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom

    Background/Purpose: Genome-wide association studies (GWAS) have to date identified over 100 genomic loci at which single nucleotide polymorphisms (SNPs) confer an increased risk of developing…
  • Abstract Number: 618 • 2018 ACR/ARHP Annual Meeting

    Blood Lymphocytes Subtypes As Biomarkers for Early Identification of Optimal Responders to Anti-TNF Treatment in Rheumatoid Arthritis

    Cristina Sobrino1, Borja Hernández-Breijo2, Israel Gañán-Nieto1, Carlota García-Hoz1, Victoria Navarro-Compán2, Ana Martínez2, Javier Bachiller1, María Gema Bonilla Hernán2, Dora Pascual-Salcedo2, Garbiñe Roy1, Mónica Vázquez1, Alejandro Balsa2, Luisa María Villar1, Chamaida Plasencia2 and Eulalia Rodríguez-Martín1, 1Immuno-Rheumatology research group, IRYCIS. Ramón y Cajal University Hospital, Madrid, Spain, 2Immuno-Rheumatology research group, IdiPaz. La Paz University Hospital, Madrid, Spain

    Background/Purpose: TNF inhibitors (TNFi) are the most common biologicalagents used as disease-modifying treatment in rheumatoid arthritis (RA). Although these drugs have contributed to change the…
  • Abstract Number: 2443 • 2018 ACR/ARHP Annual Meeting

    Trends in the Incidence of Lymphomas and Leukemias in Patients with Rheumatoid Arthritis in Spain: An Observational Cohort Study of Hospital Discharges from 1999 to 2015

    J.L Morell-Hita1, Ramon Mazzucchelli2, E Perez-Fernandez2, Javier Quirós2, Cristina Macia-Villa3, Natalia Crespí4, M Peña2, Carmen Barbadillo5, Maria Espinosa6, Hilda Godoy5, Manuel Fernández7, María Galindo8, Alberto Garcia-Vadillo9, O Guzon-Illescas2, Angela Herranz10, Cristina Martinez-Prada11, C Morado-Quiñoa11 and Virginia Villaverde García12, 1H.U.Ramón y Cajal, Madrid, Spain, 2H.U.Fundación Alcorcón, Madrid, Spain, 3Hospital Universitario Severo Ochoa, Madrid, Spain, 4C.S. La Rivota, Madrid, Spain, 5H.U. Puerta de Hierro, Madrid, Spain, 6Rheumatology, H.U. Puerta de Hierro, Madrid, Spain, 7Hospital Universitario de Guadalajara. Spain, Guadalajara, Spain, 8Servicio de Reumatología, Hospital 12 de Octubre, Madrid, Spain, 9Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, 10H.U. del Henares, Madrid, Spain, 11H.U. Clínico San Carlos, Madrid, Spain, 12Rheumatology, Hospital Universitario de Móstoles, Móstoles, Spain

    Background/Purpose: Oncohematological diseases have an increased incidence in Rheumatoid Arthritis (RA) patients. In the last years numerous studies have appeared exploring the relationship between these…
  • Abstract Number: 2929 • 2016 ACR/ARHP Annual Meeting

    The Baseline Th17 Lymphocytes Level Is a Predictive Marker of Good Response to Biologics in Rheumatoid Arthritis

    Sarah Salomon1, Caroline Guignant2, Pierre Morel3, Brigitte Gubler4, Patrice Fardellone5, Jean-Pierre Marolleau6 and Vincent Goeb7, 1Rheumatology, University Hospital of Amiens, Amiens, France, 2Immunology Laboratory, University Hospital of Amiens, Amiens, France, 3Hematology, University Hospital of Amiens, Amiens, France, 4Immunology, University Hospital of Amiens, Amiens, France, 5Department of Rheumatology, Amiens University hospital, Amiens, France, 6hematology, University Hospital of Amiens, Amiens, France, 7Rheumatology, Amiens University Hospital, Amiens, France

    Background/Purpose: In clinical daily practice, the response to biologic drugs is unpredictable in patients with rheumatoid arthritis (RA). Thus, there is a crucial need for…
  • Abstract Number: 1047 • 2015 ACR/ARHP Annual Meeting

    Characterization of Changes in Lymphocyte Subsets in Baricitinib-Treated Patients with Rheumatoid Arthritis in Two Phase 3 Studies

    Paul Emery1, Iain McInnes2, Mark C. Genovese3, Josef S. Smolen4, Joel Kremer5, Maxime Dougados6, Douglas E. Schlichting7, Terence Rooney7, Maher Issa7, Stephanie de Bono7, William L. Macias7, Veronica Rogai7, Steven H. Zuckerman7 and Peter C. Taylor8, 1Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom, 2Glasgow Biomedical Research Centre, Glasgow, United Kingdom, 3Division of Rheumatology, Stanford University Medical Center, Palo Alto, CA, 4Department of Rheumatology, Medical University of Vienna, Vienna, Austria, 5Albany Medical College, Albany, NY, 6Paris-Descartes University, Paris, France, 7Eli Lilly and Company, Indianapolis, IN, 8Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford Botnar Research Centre, Oxford, United Kingdom

    Background/Purpose: Baricitinib (bari) is an oral, reversible inhibitor of Janus kinase (JAK)1/JAK2 being developed as QD treatment for patients (pts) with RA. In phase (ph)…
  • Abstract Number: 2733 • 2015 ACR/ARHP Annual Meeting

    Effect of Abatacept on Telomerase Activity of Lymphocytes of Patients with Rheumatoid Arthritis

    Kazuhiro Otani1, Haruyasu Ito1, Kenichiro Hirai2, Kentaro Noda2, Ken Yoshida2, Isamu Kingetsu2 and Daitaro Kurosaka2, 1Internal Medicine, Jikei University School of Medicine, Tokyo, Japan, 2Division of Rheumatology, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan

    Background/Purpose: Telomere is a component of chromosome, and protects end of chromosome from various stress. Telomere shortens during cell division, and telomerase maintains telomere length.…
  • Abstract Number: 1516 • 2014 ACR/ARHP Annual Meeting

    TNF-Alpha Inhibitors Normalizes Melanocortin Receptor Subtype 2, 3 and 4 Expression in CD8+, CD14+ and CD19+ Leukocyte Subsets in Rheumatoid Arthritis

    Marlene Andersen1, Michael Kruse Meyer2, Ivan Nagaev3, Olga Nagaeva3, Jarl E.S. Wikberg4, Lucia Mincheva-Nilsson3 and Grethe N. Andersen2, 1Department of Rheumatology, Aalborg University, Hjørring, Denmark, 2Clinic of Rheumatology, Hospital of Vendsyssel/Aalborg University, Hjørring, Denmark, 3Department of Clinical Immunology, University of Umeå, Umeå, Sweden, 4Department of Pharmaceutical Biosciences, Department of Pharmaceutical Pharmacology, Uppsala, Sweden

    Background/Purpose: We examined Adalimumab´s effects on melanocortin receptor subtype (MC)1-5 gene expression in important leukocyte subsets in rheumatoid arthritis (RA). The melanocortin system is a…
  • Abstract Number: 1745 • 2014 ACR/ARHP Annual Meeting

    Memory Stem T Cells Are Selectively Enriched in Patients with Rheumatoid Arthritis, Contract upon Anti-TNF Treatment, and May Provide a Long-Term Reservoir of Arthritogenic Lymphocytes

    Nicoletta Cieri1, Giacomo Oliveira1, Raffaella Greco2, Mattia Baldini3, Elena Baldissera4, Fabio Ciceri2 and Chiara Bonini1, 1Division of Immunology, Infectious Diseases and Transplants, Experimental Hematology Unit, San Raffaele Scientific Institute, Milan, Italy, 2Division of Regenerative Medicine, Gene Therapy and Stem Cells, Hematology and Bone Marrow Transplantation Unit, San Raffaele Scientific Institute, Milan, Italy, 3Division of Immunology, Infectious Diseases and Transplants, Clinical immunopathology and advanced medical therapeutics, San Raffaele Scientific Institute, Milan, Italy, 4Clinical immunopathology and advanced medical therapeutics, San Raffaele Scientific Institute, Milan, Italy

    Background/Purpose: the T-cell memory compartment is multi-faceted and encompasses multiple subsets with divergent properties. In addition to central memory (TCM) and effector memory (TEM) cells,…
  • Abstract Number: 2404 • 2013 ACR/ARHP Annual Meeting

    CXCL13-Producing CD4 T-Cells In Rheumatoid Synovitis Are a Distinct Subset

    Shio Kobayashi1, Koichi Murata2, Hideyuki Shibuya2, Masahiro Ishikawa2, Moritoshi Furu3, Hiromu Ito3, Shuichi Matsuda2, Takeshi Watanabe4 and Hiroyuki Yoshitomi5, 1Center for Innovation in Immunoregulative Technology ant Therapeutics, Kyoto University Graduate School of Medicine, Kyoto, Japan, 2Department of Orthopaedic Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan, 3Department of the Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 4Center for Innovation in Immunoregulative Technology and Therapeutics, Kyoto University Graduate School of Medicine, Kyoto, Japan, 5Department of Innovation Center for Immunoregulation Technologies and Drugs, Kyoto University Graduate School of Medicine, Kyoto, Japan

    Background/Purpose: Ectopic lymphoid structures are frequently formed in synovial tissues of patients with rheumatoid arthritis (RA). Several reports suggested that CD4 T-cells have a crucial…
  • Abstract Number: 1400 • 2013 ACR/ARHP Annual Meeting

    Dipeptidyl Peptidase IV (DPP-IV, CD26) Levels In Patients With Rheumatoid Arthritis Treated With Biologic Therapies and Correlation With The Activity Of The Disease

    José M. Pego-Reigosa1, Oscar Cordero2, Tania López-González2, Coral Mouriño-Rodríguez3, Bruno Aspe4, Juan Viñuela-Roldán5, Rubén Varela-Calviño6, Cristina Calviño6, Marina Rodríguez-López4, Íñigo Hernández-Rodríguez4 and Víctor del Campo-Pérez7, 1Instituto de Investigación Biomédica de Vigo (IBIV), Vigo, Spain, 2Biochemistry and Molecular Biology, Universidade de Santiago de Compostela, Santiago de Compostela, Spain, 3Rheumatology, Meixoeiro Hospital, Vigo, Spain, 4Rheumatology, University Hospital Complex of Vigo, Vigo, Spain, 5Immunology, University Hospital Complex of Santiago, Santiago de Compostela, Spain, 6Biochemistry and Molecular Biology, Faculty of Pharmacy, University of Santiago de Compostela, Santiago de Compostela, Spain, 7Preventive Medicine and Epidemiology, University Hospital Complex of Vigo, Vigo, Spain

    Background/Purpose: Dipeptidyl peptidase IV (DPP-IV, CD26), a protease cleaving N-terminal X-Pro dipeptides from selected proteins including chemokines is expressed both as a soluble form and…
  • Abstract Number: 1385 • 2013 ACR/ARHP Annual Meeting

    A Study Of Natural Killer Cell Subfractions In Abatacept Therapy For Rheumatoid Arthritis

    Masao Sato1, Masao Takemura2, Ryuki Shinohe1, Yasuko Yamamoto3 and Kuniaki Saito3, 1Orthopaedic Surgery, Gifu University, Gifu, Japan, 2Informative Clinical Medicine, Gifu University, Gifu, Japan, 3Human Health Science, Kyoto University, Kyoto, Japan

    Background/Purpose: Inflammatory cytokines and cell-mediated immunity function of mainly lymphocytes are complicatedly involved in disease onset of rheumatoid arthritis (RA). Recently, together with biologicals such…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology